During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...

“The end game is trying to relate [dopamine signaling] back to schizophrenia and other disorders with working memory impairment,” study coauthor Joshua Roffman of MGH and Harvard University told The ...

Dopamine’s effects in the brain are mediated by postsynaptic D1 and D2 receptors. Adenosine A1 and A2A receptors are uniquely positioned to counteract the excessive stimulation of dopamine receptors ...

Intriguingly, Hensch's team identified a brain mechanism underlying the attention deficits: a difference in the balance of ...

To this end, radioreceptor and functional studies of these three compounds were conducted at each of the known molecular isoforms of the dopamine receptors in several transfection systems ...